Advance Search

Evaluation of galectin-3 and other biochemical parameters in chronic kidney disease patients on hemodialysis in Erbil city

Zereen M. Abdullah
Department of Clinical Biochemistry, College of Health Sciences, Hawler Medical University, Erbil, Iraq.
Kamaran Y. Mohammadamin
Department of Clinical Biochemistry, University of Salahaddin, Erbil, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2023 Zereen M. Abdullah, Kamaran Y. Mohammadamin (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objective: Chronic kidney disease represents a leading cause of death in many countries. End-stage renal disease is the final stage of chronic kidney disease, in which the kidneys are no longer function well enough for the patient to live without renal replacement therapy. Galectin-3 is a soluble beta-galactoside-binding lectin protein involved in the fibrosis of many solid organs, including the heart and kidney. This study aimed to evaluate galectin-3 and other biochemical parameters in hemodialysis patients.

Methods: The design is a cross-sectional study with a comparison group. A total of 70 chronic kidney disease patients on regular hemodialysis from Erbil Dialysis Center in Erbil City and 68 healthy subjects were enrolled. The serum levels of galectin-3 were determined by enzyme-linked immunosorbent assay method.

Results: The mean level of serum galectin-3 was non-significantly higher in hemodialysis patients compared to the control group (P = 0.594). However, the serum level of galectin-3 was significantly higher in hemodialysis patients with cardiovascular disease compared to hemodialysis patients without cardiovascular disease (P = 0.0220). Serum galectin-3 level was significantly higher in hemodialysis patients aged 36-50 and 51-70 years old compared to hemodialysis patients aged 20-35 years old (P = 0.013, P = 0.026), respectively.

Conclusion: Serum galectin-3 might be used as a biomarker for hemodialysis patients with cardiovascular disease.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. Tsai M-T, Ou S-M, Chen H-Y, Tseng W-C, Lee K-H, Yang C-Y, et al. Relationship between circulating galectin-3, systemic inflammation, and protein-energy wasting in chronic hemodialysis patients. Nutrients. 2021; 13(8):2803. https://doi.org/10.3390/nu13082803
  2. Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, Ärnlöv J, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015; 30(suppl_4):iv6–iv16. https://doi.org/10.1093/ndt/gfv131
  3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One. 2016; 11(7):e0158765. https://doi.org/10.1371/journal. pone.0158765
  4. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11):825–30. https://doi.org/10.7326/0003-4819-158-11-201306040-00007
  5. Alexander N, Matsushita K, Sang Y, Ballew S, Mahmoodi BK, Astor BC, et al. Kidney measures with diabetes and hypertension on cardiovascular disease: the Atherosclerosis Risk in Communities Study. Am J Nephrol. 2015; 41(4-5):409–17. https://doi.org/10.1159/ 000433450
  6. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018; 33(suppl_3):iii28–34. https://doi.org/10.1093/ndt/gfy174
  7. Vadakedath S, Kandi V. Dialysis: A Review of the Mechanisms Underlying Complications in the Management of Chronic Renal Failure. Cureus. 2017; 9(8):e1603. https://doi.org/10.7759/cureus. 1603
  8. Abbasi MA, Chertow GM, Hall YN. End-stage renal disease. BMJ Clin Evid. 2010. https://pubmed.ncbi.nlm.nih.gov/21418665
  9. Liu S, Wu Q, Zhang S, Wang Z, Liu H, Teng L, et al. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. BMC Nephrol. 2022; 23(1):1–9. https://doi.org/10.1186/s12882-021-02636-z
  10. Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022; 18(6):378–95. https://doi.org/10.1038/s41581-022-00542-7
  11. Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018; 41(2):599–614. https://doi.org/10.3892/ijmm.2017.3311
  12. Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules. 2021; 12(1):46. https://doi.org/ 10.3390/biom12010046
  13. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine-and cystatin C–based equations to estimate GFR without race.N Engl J Med. 2021; 385(19):1737–49. https://doi.org/10.1056/NEJMoa2102953
  14. Sultan S, Nasir K, Qureshi R, Dhrolia M, Ahmad A. Assessment of the nutritional status of the hemodialysis patients by anthropometric measurements. Cureus. 2021; 13(10):e18605. https://doi.org/10.7759/cureus.18605
  15. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021; 52(2):98–107. https://doi.org/ 10.1159/000514550
  16. Ali SS, Naqshbandi VA, Sedeeq SA. Dialysis-Related Factors Affecting Activities of Daily Living in Patients on Hemodialysis in Erbil City. EJNM. 2021; 4(1):1–14. https://doi.org/10.15218/ejnm.2021.01
  17. Li H, Wang S. Cardiovascular disease in hemodialysis patients. Hemodialysis: Intech Open. 2013. https://doi.org/10.5772/53071
  18. Pandya D, Nagrajappa AK, Ravi KS. Assessment and correlation of urea and creatinine levels in saliva and serum of patients with chronic kidney disease, diabetes and hypertension–a research study. JCDR. 2016; 10(10):ZC58. https://doi.org/10.7860/JCDR/2016/20294.8651
  19. Gupta K, Mahajan R. Coronary risk factors in maintenance hemodialysis patients: Who is the culprit–hemodialysis or chronic renal failure? Int J Appl Basic Med Res. 2011; 1(1):11. https://doi.org/10.4103/2229-516X.81973
  20. Meijers WC, van der Velde AR, Ruifrok WP, Schroten NF, Dokter MM, Damman K, et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc. 2014; 3(5):e000962. https://doi.org/10.1161/JAHA.114. 000962
  21. De Boer RA, Van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, Van Gilst WH, Hillege HL, et al. The fibrosis marker galectin‐3 and outcome in the general population. J Intern Med. 2012; 272(1):55–64. https://doi.org/10.1111/j.1365-2796.2011.02476.x
  22. Badve SV, Paul SK, Klein K, Clayton PA, Hawley CM, Brown FG, et al. The association between body mass index and mortality in incident dialysis patients. PLoS One. 2014; 9(12):e114897. https://doi.org/10.1371/journal.pone.0114897
  23. Çelik G, Oc B, Kara I, Yılmaz M, Yuceaktas A, Apiliogullari S. Comparison of nutritional parameters among adult and elderly hemodialysis patients. Int J Med Sci. 2011; 8(7):628. https://doi.org/10.7150/ijms.8.628
How to Cite
M. Abdullah, Z., & Y. Mohammadamin, K. (2023). Evaluation of galectin-3 and other biochemical parameters in chronic kidney disease patients on hemodialysis in Erbil city. Zanco Journal of Medical Sciences (Zanco J Med Sci), 27(2), 176–183. https://doi.org/10.15218/zjms.2023.020

Send mail to Author

Send Cancel